Home
ABOUT US
Overview
Business Model
Board of Directors
Management Team
History & Milestones
Sustainability
R & D PIPELINE
INVESTORS
Investor Overview
Financial Reports
Shareholders’ Meetings
Events & Presentations
NEWS
CAREERS
CONTACT
EN
中文版
NEW DRUGS FOR THE TREATMENT OF CANCER
PharmaEngine
We Race With You
DISCOVER MORE
CANCER TREATMENT PRODUCTS
ONIVYDE
A Revolutionary Durg
DISCOVER ONIVYDE
History
&
Milestones
Onivyde
PharmaEngine announces first patient dosed in Phase I trial of PEP07 for hematological cancers
2023/8/15
PharmaEngine announces EMA’s acceptance of ONIVYDE®’s Type II Variation application
2023/7/11
PharmaEngine files post-approval change application for a new indication of ONIVYDE® to TFDA
2023/6/21
PEP07
R&D Pipeline
Events & Presentations
Organization
Our Partners
Contact Us
Go To Top